A Phase 1 interventional study of MF-300 SAD and Placebo in Healthy Volunteers, sponsored by Epirium Bio Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Epirium Bio Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose [SAD] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose [MAD] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (> 65 to ≤75 years of age) healthy adult subjects.
Part 1a is a double blind, randomized, placebo controlled, sequential SAD trial in healthy male or female volunteers. Volunteers will receive oral study drug (MF-300 or placebo) single dose administration. The dose levels will be tested sequentially until safety evaluation identifies a non-tolerated dose in the investigated population or when sustained MF-300 plasma levels are reaching the exposure supported by the available preclinical toxicokinetic data. Approximately 5 dose groups (non-elderly population) will provide a series increasing dose levels. An additional SAD dose group will evaluate an elderly population, with a dose selected based on safety and PK data from the 5 non-elderly SAD cohorts but not higher than what has been determined as generally safe and tolerated in the non-elderly population. Overall, no less than 48 subjects (assuming 6 cohorts of 8 subjects each) may complete the SAD study.
One tolerated dose completed in Part 1a will be selected for the evaluation of food effect (Part 1b). The dose will be selected on the basis of accumulated safety and PK information from the SAD phase. Food effect assessment is to be performed using the non-elderly population only. The food effect study is a randomized, 2-period, 2-sequence, open-label, crossover study. Approximately 12 subjects will be randomly assigned to 1 of the 2 treatment sequences (6 subjects per sequence) in which they receive MF-300 following a 10-hour fast or following a high-fat breakfast.
Part 2 is a double blind, randomized, placebo controlled, sequential MAD trial in healthy male or female volunteers. Volunteers will receive oral study drug (MF-300 or placebo) daily for 5 days as anticipated to achieved MF-300 steady state. The frequency of administration (once daily (QD)) and the duration of therapy required to achieve steady state (5 daily doses) were selected on the basis of allometric modeling from available toxicokinetic data but may be adapted based on MF-300 PK observed in the SAD cohorts previously completed. Three dose groups (non-elderly population) will provide a series increasing dose levels. The start of the MAD and SAD parts will be staggered, and a MAD dose cohort may be initiated when the corresponding SAD cohort at the next higher MF-300 dose has been cleared as safe and the food effect cohort has been completed. A fourth MAD dose group will be evaluated in the elderly population.
Epirium Bio Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-Elderly Cohorts:
Female subjects must either:
Male subjects must be non-fertile, vasectomized (vasectomy performed 4 months or more prior to the first dosing), or truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for duration of study and for 90 days from last administration of study drug or heterosexual partner is not of child bearing potential or subject is willing to continue using two medically acceptable form of birth control from Day -1 until at least 90 days after the last administration of study drug. Highly effective contraceptive methods include:
Elderly Cohorts:
To be eligible for this study, subjects must meet all of the following inclusion criteria:
Healthy male or non-pregnant, non-lactating female subjects > 65 to ≤ 75 years of age at time of first dosing. Subjects with a history of and/or current well-controlled medical conditions may be enrolled so long as the investigator, in consultation with the medical monitor, are of the opinion that such conditions will not interfere with the safety of the subjects and that the subjects are otherwise in good general health. Some examples of allowable well-controlled medical conditions, in otherwise healthy subjects, include, but are not limited to the following:
Male subjects must be non-fertile, vasectomized (vasectomy performed 4 months or more prior to the first dosing), or truly abstinent of heterosexual intercourse as their usual and preferred lifestyle and agree to remain abstinent for duration of study and for 90 days from last administration of study drug or heterosexual partner is not of child bearing potential or subject is willing to continue using two medically acceptable form of birth control from Day -1 until at least 90 days after the last administration of study drug. Highly effective contraceptive methods include:
Exclusion Criteria:
Non-Elderly Cohorts:
Subjects who meet any of the following criteria will be excluded from participating in the study:
Elderly Cohorts:
Subjects who meet any of the following criteria will be excluded from participating in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 out of 8 participants per cohort (up to 6 cohorts) will be randomized to receive a single dose of MF-300 in a fasted state
Drug: MF-300 SAD
2 out of 8 participants per cohort (up to 6 cohorts) will be randomized to receive a single oral dose of Placebo in a fasted state
Drug: Placebo
12 participants will receive a single dose of MF-300 in fed and fasting conditions
Drug: MF-300 Food Effect
8 out of 10 participants per cohort (up to 4 cohorts) will be randomized to receive once daily oral doses of MF-300 on Days 1-5 in a fasted state
Drug: MF-300 MAD
2 out of 10 participants per cohort (up to 4 cohorts) will be randomized to receive once daily oral doses of Placebo on Days 1-5 in a fasted state
Drug: Placebo
oral capsule at doses of 75mg, 125 mg, 250 mg, 500 mg, or 800 mg
Also known as: MF-300
matching placebo oral capsule
oral capsule at a dose of 500 mg
Also known as: MF-300
oral capsule at doses of 75mg, 125 mg, or 200 mg
Also known as: MF-300
Proportion of participants with treatment-emergent adverse events (TEAEs)
Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment
Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
Proportion of participants with serious adverse events (SAEs)
An SAE is any untoward medical occurrence at any dose which results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event (IME)
Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
Proportion of participants with any TEAE leading to premature discontinuation of study intervention
Treatment-emergent AEs (TEAEs): AE that either commenced following initiation of study treatment or was present prior to study treatment but increased in frequency or severity following initiation of study treatment
Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
Part 1 SAD Cmax
Plasma PK analysis of maximum observed plasma concentration (Cmax) for MF-300 following a single dose in healthy subjects
Time frame: up to 72 hours
Part 1 SAD Tmax
Plasma PK time corresponding to the maximum observed plasma concentration (Tmax) for MF-300 following a single dose in healthy subjects
Time frame: up to 72 hours
Part 1 SAD t½
Plasma PK apparent terminal elimination half-life in plasma (t½) for MF-300 following a single dose in healthy subjects
Time frame: up to 72 hours
Part 1 SAD AUC0-∞
Plasma PK area under the plasma concentration vs. time curve from time zero extrapolated to infinity (AUC0-∞) for MF-300 following a single dose in healthy subjects
Time frame: up to 72 hours
Part 2 MAD Cmax
Plasma PK maximum observed plasma concentration (Cmax) for MF-300 following multiple doses in healthy subjects
Time frame: up to Day 6
Part 2 MAD Ctrough
Plasma PK trough plasma concentration (Ctrough) for MF-300 following multiple doses in healthy subjects
Time frame: up to Day 6
Part 2 MAD Tmax
Plasma PK time corresponding to the maximum observed plasma concentration (Tmax) for MF-300 following multiple doses in healthy subjects
Time frame: up to Day 6
Part 2 MAD t½
Plasma PK Plasma apparent terminal elimination half-life in plasma (t½) for MF-300 following multiple doses in healthy subjects
Time frame: up to Day 6
Part 2 MAD AUC0-last
Plasma PK area under the plasma concentration vs. time curve from time zero to last measurable concentration (AUC0-last) for MF-300 following multiple doses in healthy subjects
Time frame: up to Day 6
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Oct 2025, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epirium Bio Inc.